• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Virta Adds Prediabetes and Obesity Reversal to Services

by Jasmine Pennic 10/07/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Virta Expands Offerings to Treat New Group of Chronic Illnesses

What You Should Know:

– Virta is expanding its suite of treatment options to include prediabetes reversal, obesity reversal, and type 2 diabetes management.

– By making this crucial expansion, Virta can scale its treatment to support the tens of millions of additional patients with prediabetes and obesity, as provide an on-ramp to reversal for those with T2D that aren’t yet ready to reverse. 


Virta Health, the leader in type 2 diabetes reversal, today introduced the addition of new services including prediabetes reversal, obesity treatment, and provider-led management for type 2 diabetes. The expansion provides payers and covered beneficiaries a single, full-service virtual clinic that offers industry-leading outcomes for the most critical needs in metabolic health.

Virta’s fully-virtual, high-touch model demonstrates hope for change, and stands in stark contrast to approaches that only slow the diabetes downward spiral, as opposed to reversing it. Virta provides individualized guidance from medical providers and behavioral specialists, whenever and wherever it is needed. Patients interact with their dedicated clinical team often multiple times per day. This novel telehealth approach—called Continuous Remote Care—ensures successful adoption of Virta’s individualized medical nutrition therapies and long-lasting results.


Why It Matters

Nearly half of adults in the United States suffer from obesity, prediabetes, or type 2 diabetes. Thirty people die per hour of diabetes-related causes. The economic burden continues to grow, and people with diabetes incur nearly $17,000 in medical expenses per year. They are also at high risk for severe illness from COVID-19, and risk of dying from the disease is twice as high compared to those without diabetes.

Obesity and prediabetes patients will benefit from the same treatment that delivers the sustained type 2 diabetes reversal outcomes in Virta’s clinical trial and commercially-covered population. Patients receiving type 2 diabetes management will receive support from a provider-led care team, with personalized guidance and an option for a seamless transition to Virta’s reversal treatment. All patients will receive individualized care via Virta’s provider-led Continuous Remote Care platform.

Virta Type 2 Diabetes Reversal Results

Virta’s results in type 2 diabetes reversal have fueled continued triple-digit year-over-year growth for the company while creating strong demand to bring Virta’s evidence-based approach to other metabolic conditions. In Virta’s peer-reviewed clinical trial results, 60% of people at one-year reverse type 2 diabetes, and 94% reduce insulin use or eliminate it altogether.

Additionally, patients completing one year of the Virta Treatment experience 14% weight loss. This figure exceeds the goal of the National Diabetes Prevention Program and the FDA benchmark for weight loss drugs by nearly 200%.

“This expansion provides our commercial partners and patients with the transformational outcomes they’ve come to expect from Virta, but don’t receive from other solutions on the market,” said Sami Inkinen, CEO & co-founder of Virta Health. “We can now meet every patient wherever they are on their metabolic health journey, while uniquely offering a path to reversing their chronic disease.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Clinical Trial, diabetes, Diabetes Management, Diabetes Management Platform, Diabetes Prevention Platform, Diabetes Reversal, FDA, insulin, model, Obesity, Partners, Payers, risk, Type 2 Diabetes, Virta Health

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

2026 Predictions & Trends

Healthcare 2026 Forecast: Executives on AI Survival, Financial Reckoning, and the End of Point Solutions

2026 Healthcare Executive Predictions: Why the AI “Pilot Era” Is Officially Over

Most-Read

HHS Launches 'OneHHS' AI Strategy to Integrate AI Across CDC, CMS, and FDA for Efficiency and Public Trust

HHS Launches ‘OneHHS’ AI Strategy to Integrate AI Across CDC, CMS, and FDA for Efficiency and Public Trust

Kristen Hartsell, VP of Clinical Services, RedSail Technologies

The Pharmacy Closures Crisis: How Independent Pharmacies Are Fixing Pharmacy Deserts

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

The VBC Paradox: Why Hospitals Are Doubling Down on Value-Based Care While Revenue at Risk Lags

The VBC Paradox: Why Hospitals Are Doubling Down on Value-Based Care While Revenue at Risk Lags

Tebra Secures $250M to Challenge Legacy EHRs with AI-Powered Automation

Tebra Secures $250M to Challenge Legacy EHRs with AI-Powered Automation

AstraZeneca Selects Salesforce Agentforce Life Sciences to Deploy AI-Powered Global Customer Engagement

AstraZeneca Selects Salesforce Agentforce Life Sciences to Deploy AI-Powered Global Customer Engagement

Aidoc Partners with NVIDIA MONAI to Scale Open-Source Clinical AI

Aidoc Partners with NVIDIA MONAI to Scale Open-Source Clinical AI

RapidAI Secures FDA Clearance for Five New Deep Clinical AI Modules, Expanding Enterprise Imaging Platform

RapidAI and AWS Deepen Partnership to Scale Clinical AI in Healthcare

Greece and Sword Health to Build AI-Powered Healthcare Front Door

Greece and Sword Health to Build AI-Powered Healthcare Front Door

GE HealthCare Acquires Intelerad for $2.3B to Create Cloud-First, AI-Enabled Imaging Ecosystem

GE HealthCare Acquires Intelerad for $2.3B to Create Cloud-First, AI-Enabled Imaging Ecosystem

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |